169 related articles for article (PubMed ID: 31117125)
21. Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels.
Xiong WH; Brown RL; Reed B; Burke NS; Duvoisin RM; Morgans CW
Invest Ophthalmol Vis Sci; 2015 Feb; 56(2):1367-73. PubMed ID: 25650413
[TBL] [Abstract][Full Text] [Related]
22. The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi.
Lu S; Slominski A; Yang SE; Sheehan C; Ross J; Carlson JA
J Cutan Pathol; 2010 Apr; 37 Suppl 1(Suppl 1):26-40. PubMed ID: 20482673
[TBL] [Abstract][Full Text] [Related]
23. TRPM1 (melastatin) expression is an independent predictor of overall survival in clinical AJCC stage I and II melanoma patients.
Brożyna AA; Guo H; Yang SE; Cornelius L; Linette G; Murphy M; Sheehan C; Ross J; Slominski A; Carlson JA
J Cutan Pathol; 2017 Apr; 44(4):328-337. PubMed ID: 27987328
[TBL] [Abstract][Full Text] [Related]
24. Melanoma-associated retinopathy.
Elsheikh S; Gurney SP; Burdon MA
Clin Exp Dermatol; 2020 Mar; 45(2):147-152. PubMed ID: 31742740
[TBL] [Abstract][Full Text] [Related]
25. [Paraneoplastic retinopathy].
Ueno S
Nihon Rinsho; 2015 Sep; 73 Suppl 7():768-75. PubMed ID: 26480792
[No Abstract] [Full Text] [Related]
26. TRPM1 mutations are associated with the complete form of congenital stationary night blindness.
Nakamura M; Sanuki R; Yasuma TR; Onishi A; Nishiguchi KM; Koike C; Kadowaki M; Kondo M; Miyake Y; Furukawa T
Mol Vis; 2010 Mar; 16():425-37. PubMed ID: 20300565
[TBL] [Abstract][Full Text] [Related]
27. [Melanoma-associated retinopathy with night blindness. Case report].
Klopfer M; Schmidt T; Leipert KP; Ugi I; Boeck K; Hofmann S
Ophthalmologe; 1997 Aug; 94(8):563-7. PubMed ID: 9376694
[TBL] [Abstract][Full Text] [Related]
28. TRPM1 forms ion channels associated with melanin content in melanocytes.
Oancea E; Vriens J; Brauchi S; Jun J; Splawski I; Clapham DE
Sci Signal; 2009 May; 2(70):ra21. PubMed ID: 19436059
[TBL] [Abstract][Full Text] [Related]
29. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.
Karatsai E; Robson AG; Taylor SRJ
JAMA Ophthalmol; 2019 May; 137(5):564-567. PubMed ID: 30896772
[TBL] [Abstract][Full Text] [Related]
30. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV.
Ladewig G; Reinhold U; Thirkill CE; Kerber A; Tilgen W; Pföhler C
Br J Dermatol; 2005 May; 152(5):931-8. PubMed ID: 15888149
[TBL] [Abstract][Full Text] [Related]
31. Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature.
Aronow ME; Adamus G; Abu-Asab M; Wang Y; Chan CC; Zakov ZN; Singh AD
Surv Ophthalmol; 2012 Nov; 57(6):558-64. PubMed ID: 22784677
[TBL] [Abstract][Full Text] [Related]
32. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma.
Weinstein JM; Kelman SE; Bresnick GH; Kornguth SE
Ophthalmology; 1994 Jul; 101(7):1236-43. PubMed ID: 8035987
[TBL] [Abstract][Full Text] [Related]
33. TRPM1 is required for the depolarizing light response in retinal ON-bipolar cells.
Morgans CW; Zhang J; Jeffrey BG; Nelson SM; Burke NS; Duvoisin RM; Brown RL
Proc Natl Acad Sci U S A; 2009 Nov; 106(45):19174-8. PubMed ID: 19861548
[TBL] [Abstract][Full Text] [Related]
34. Anti-TRPM1 autoantibodies.
Adamus G
Clin Exp Ophthalmol; 2019 Jan; 47(1):147-148. PubMed ID: 30047206
[No Abstract] [Full Text] [Related]
35. [Paraneoplastic retinopathy and optic neuropathy].
Ikawa M; Kuriyama M
Brain Nerve; 2010 Apr; 62(4):371-6. PubMed ID: 20420177
[TBL] [Abstract][Full Text] [Related]
36. Depolarizing bipolar cell dysfunction due to a Trpm1 point mutation.
Peachey NS; Pearring JN; Bojang P; Hirschtritt ME; Sturgill-Short G; Ray TA; Furukawa T; Koike C; Goldberg AF; Shen Y; McCall MA; Nawy S; Nishina PM; Gregg RG
J Neurophysiol; 2012 Nov; 108(9):2442-51. PubMed ID: 22896717
[TBL] [Abstract][Full Text] [Related]
37. Different Activity Patterns in Retinal Ganglion Cells of TRPM1 and mGluR6 Knockout Mice.
Takeuchi H; Horie S; Moritoh S; Matsushima H; Hori T; Kimori Y; Kitano K; Tsubo Y; Tachibana M; Koike C
Biomed Res Int; 2018; 2018():2963232. PubMed ID: 29854741
[TBL] [Abstract][Full Text] [Related]
38. Anti-TRPM1 antibodies in patients with retinal degeneration.
Nishiguchi KM; Fujita K; Inoue T; Nakazawa T
Clin Exp Ophthalmol; 2018 Dec; 46(9):1087-1089. PubMed ID: 29927037
[No Abstract] [Full Text] [Related]
39. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo.
Lei B; Bush RA; Milam AH; Sieving PA
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):262-6. PubMed ID: 10634629
[TBL] [Abstract][Full Text] [Related]
40. The TRPM1 Channel Is Required for Development of the Rod ON Bipolar Cell-AII Amacrine Cell Pathway in the Retinal Circuit.
Kozuka T; Chaya T; Tamalu F; Shimada M; Fujimaki-Aoba K; Kuwahara R; Watanabe SI; Furukawa T
J Neurosci; 2017 Oct; 37(41):9889-9900. PubMed ID: 28899920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
